Precision cancer medicine 2025: some concerns

Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28:658–665.

https://doi.org/10.1038/s41591-022-01717-2 DOI: https://doi.org/10.1038/s41591-022-01717-2

Song I-W, Vo HH, Chen Y-S, Baysal MA, Kahle M, Johnson A, et al. Precision oncology: evolving clinical trials across tumor types. Cancers. 2023;15:1967.

https://doi.org/10.3390/cancers15071967 DOI: https://doi.org/10.3390/cancers15071967

Shah NM, Meric-Bernstam F. The present and future of precision oncology and tumor-agnostic therapeutic approaches. Oncologist. 2025;30:oyaf152.

https://doi.org/10.1093/oncolo/oyaf152 DOI: https://doi.org/10.1093/oncolo/oyaf152

Westphalen CB, Martins-Branco D, Beal JR, Cardone C, Coleman N, Schram AM, et al. The ESMO tumour-agnostic classifier and screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. Ann Oncol. 2024;35:936–953.

https://doi.org/10.1016/j.annonc.2024.07.730 DOI: https://doi.org/10.1016/j.annonc.2024.07.730

Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:1–17.

https://doi.org/10.1038/s41571-018-0113-0 DOI: https://doi.org/10.1038/s41571-018-0113-0

Andrei P, Battuello P, Grasso G, Rovera E, Tesio N, Bardelli A. Integrated approaches for precision oncology in colorectal cancer: the more you know, the better. Semin Cancer Biol. 2022;84:199–213.

https://doi.org/10.1016/j.semcancer.2021.04.007 DOI: https://doi.org/10.1016/j.semcancer.2021.04.007

Armando RG, Gómez DLM, Gomez DE. New drugs are not enough –– drug repositioning in oncology: an update. Int J Oncol. 2020;56:1–34.

https://doi.org/10.3892/ijo.2020.4966 DOI: https://doi.org/10.3892/ijo.2020.4966

Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, et al. Therapeutic drug monitoring based precision dosing of oral targeted therapies in oncology: a prospective multicentre study. Ann Oncol. 2022;33(10):1071–82.

https://doi.org/10.1016/j.annonc.2022.06.010 DOI: https://doi.org/10.1016/j.annonc.2022.06.010

Blake SJ, Wolf Y, Boursi B, Lynn DJ. Role of the microbiota in response to and recovery from cancer therapy. Nat Rev Immunol. 2024;24:308–325.

https://doi.org/10.1038/s41577-023-00951-0 DOI: https://doi.org/10.1038/s41577-023-00951-0

Passaro A, Bakir MA, Hamilton EG, Diehn M, André F, Roy-Chowdhuri S, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024;187:1617–35.

https://doi.org/10.1016/j.cell.2024.02.041 DOI: https://doi.org/10.1016/j.cell.2024.02.041

Chang T-G, Park S, Schäffer AA, Jiang P, Ruppin E. Hallmarks of artificial intelligence contributions to precision oncology. Nat Cancer. 2025;6:417–431.

https://doi.org/10.1038/s43018-025-00917-2 DOI: https://doi.org/10.1038/s43018-025-00917-2

Sadée C, Testa S, Barba T, Hartmann K, Schuessler M, Thieme A, et al. Medical digital twins: enabling precision medicine and medical artificial intelligence. Lancet Digit Health. 2025;7(7):100864.

https://doi.org/10.1016/j.landig.2025.02.004 DOI: https://doi.org/10.1016/j.landig.2025.02.004

Elez E, Yoshino T, Shen L, Lonardi S, Cutsem EV, Eng C, et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer. N Engl J Med. 2025;392:2425–37.

https://doi.org/10.1056/NEJMoa2501912 DOI: https://doi.org/10.1056/NEJMoa2501912

Tourneau CL, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, et al. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. Eur J Cancer. 2023;194:113278.

https://doi.org/10.1016/j.ejca.2023.113278 DOI: https://doi.org/10.1016/j.ejca.2023.113278

Grauman Å, Ancillotti M, Veldwijk J, Mascalzoni D. Precision cancer medicine and the doctor-patient relationship: a systematic review and narrative synthesis. BMC Med Inform Decis Mak. 2023;23:286.

https://doi.org/10.1186/s12911-023-02395-x DOI: https://doi.org/10.1186/s12911-023-02395-x

DeCarli K, Bradbury A, Lopez AM, Camacho P, Chatwal MS, Friese CR, et al. Ethical and clinical considerations in ordering and responding to molecular diagnostics and circulating tumor DNA as the science evolves. JCO Oncol Pr. 2024;20:1508–14.

https://doi.org/10.1200/OP-24-00481 DOI: https://doi.org/10.1200/OP-24-00481

Schneider BP, Jiang G, Ballinger TJ, Shen F, Chitambar C, Nanda R, et al. BRE12-158: a postneoadjuvant, randomized phase II Trial of personalized therapy versus treatment of physician’s choice for patients with residual triple-negative breast cancer. J Clin Oncol. 2022;40:345–55.

https://doi.org/10.1200/JCO.21.01657 DOI: https://doi.org/10.1200/JCO.21.01657

Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, et al. Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022;610:343–8.

https://doi.org/10.1038/s41586-022-05068-3 DOI: https://doi.org/10.1038/s41586-022-05068-3

Tourneau CL, Delord J-P, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–34.

https://doi.org/10.1016/S1470-2045(15)00188-6 DOI: https://doi.org/10.1016/S1470-2045(15)00188-6

Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med. 2022;14:101.

https://doi.org/10.1186/s13073-022-01102-1 DOI: https://doi.org/10.1186/s13073-022-01102-1

Taskén K, Mohammad SFH, Fagereng GL, Falk RS, Helland Å, van Wallwijk van Doorn-Khosrovani SB, et al. PCM4EU and PRIME-ROSE: collaboration for implementation of precision cancer medicine in Europe. Acta Oncol. 2024;63:34791.

https://doi.org/10.2340/1651-226X.2024.34791 DOI: https://doi.org/10.2340/1651-226X.2024.34791

Taskén K, Mahon P. Accelerating precision oncology by converging pragmatic trials and real-world evidence. Nat Rev Drug Discov. 2025; Mar 13, online ahead of print.

https://doi.org/10.1038/d41573-025-00047-5 DOI: https://doi.org/10.1038/d41573-025-00047-5

Popat S, Liu SV, Scheuer N, Hsu GG, Lockhart A, Ramagopalan SV, et al. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of pralsetinib in non-small cell lung cancer. Nat Commun. 2022;13:3500.

https://doi.org/10.1038/s41467-022-30908-1 DOI: https://doi.org/10.1038/s41467-022-30908-1

Mahon P, Chatzitheofilou I, Dekker A, Fernández X, Hall G, Helland A, et al. A federated learning system for precision oncology in Europe: DigiONE. Nat Med. 2024;30:334–7.

https://doi.org/10.1038/s41591-023-02715-8 DOI: https://doi.org/10.1038/s41591-023-02715-8

Kessels R, May AM, Koopman M, Roes KCB. The trial within cohorts (TwiCs) study design in oncology: experience and methodological reflections. BMC Med Res Methodol. 2023;23:117.

https://doi.org/10.1186/s12874-023-01941-5 DOI: https://doi.org/10.1186/s12874-023-01941-5